

DWS Investment GmbH

DWS Health Care Typ O

Semiannual Report 2021/2022



DWS Health Care Typ 0

Contents

Semiannual report 2021/2022

for the period from October 1, 2021, through March 31, 2022

(in accordance with article 103 of the German Investment Code (KAGB))

General information 2

Semiannual report

DWS Health Care Typ O 6

General information

Performance

The investment return, or performance, of a mutual fund investment is measured by the change in value of the fund's units. The net asset values per unit (= redemption prices) with the addition of intervening distributions, which are, for example, reinvested free of charge within the scope of investment accounts at DWS Investment GmbH, are used as the basis for calculating the value; in the case of domestic reinvesting funds, the domestic investment income tax – following any deduction of foreign withholding tax – plus solidarity surcharge charged to the fund are added. Performance is calculated in accordance with the "BVI method". Past performance is not a guide to future results.

The corresponding benchmarks – if available – are also presented in the report. All financial data in this publication is as of **March 31, 2022** (unless otherwise stated).

Sales prospectuses

The sole binding basis for a purchase are the current version of the sales prospectus, including the Terms and Conditions of Investment, and the key investor information document, which are available from DWS Investment GmbH or any branch of Deutsche Bank AG as well as from other paying agents.

Information about the all-in fee

The all-in fee does not include the following expenses:

- a) any costs that may arise in connection with the acquisition and disposal of assets;
- b) any taxes that may arise in connection with administrative and custodial costs;
- c) the costs of asserting and enforcing the legal claims of the investment fund.

The details of the fee structure are set out in the current sales prospectus.

Issue and redemption prices

Each exchange trading day on the Internet:

www.dws.de

Russia/Ukraine crisis

The escalating conflict between Russia and Ukraine marked a dramatic turning point in Europe, which, among other things, is expected to have a lasting effect on Europe's security architecture and energy policies and to cause considerable volatility. However, the specific or possible medium to long-term effects of the crisis on the economy, individual markets and sectors, as well as the social implications, cannot be conclusively assessed due to the uncertainty at the time of preparing this report. The Asset Management Company of the investment fund is therefore continuing its efforts, within the framework of its risk management strategy, to assess these uncertainties and their possible impact on the activities, liquidity and performance of the investment fund. The Asset Management Company is taking all measures deemed appropriate to protect investor interests to the greatest possible extent.

Coronavirus crisis

The coronavirus has spread since January 2020 and has subsequently led to a serious economic crisis. The rapid proliferation of the virus was reflected in, among other things, significant price market distortions and substantially increased volatility at the same time. Restrictions on freedom of movement, repeated lockdown measures, production stoppages, as well as disrupted supply chains, are exerting major pressure on downstream economic processes, which caused global economic prospects to deteriorate considerably. In the interim, noticeable recoveries and some new highs were to be observed in the markets – due, among other factors, to monetary and fiscal policy support programs and extensive vaccination and testing campaigns. Nevertheless, the specific or possible medium-to-long-term effects of the crisis on the economy, individual markets and sectors as well as the social implications in respect of the vigorous global spread of the virus or the emergence of various mutations and the associated high level of uncertainty at the time of preparing this report cannot be reliably assessed. There may therefore still be a significant impact on the respective investment fund's assets. A high level of uncertainty exists in relation to the financial implications of the pandemic, as these are dependent on external factors such as the spread of the virus/emerging variants and the measures taken by individual governments and central banks, the successful stemming of the development of infection rates in connection with vaccination rates and the speedy and sustainable restart of the economy.

The Asset Management Company of the investment fund is therefore continuing its efforts, within the framework of its risk management strategy, to assess these uncertainties and their possible impact on the activities, liquidity and performance of the investment fund. The Asset Management Company is taking all measures deemed appropriate to protect investor interests to the greatest possible extent. In coordination with the service providers, the Asset Management Company observed the consequences of the coronavirus crisis and adequately included its impact on the investment fund and the markets in which the investment fund invests into its decision-making processes. As of the date of this report, no significant redemption requests had been made in respect of the investment fund; the effects on the investment fund's unit certificate transactions are continuously monitored by the Asset Management Company; the performance capability of the most important service providers did not experience any significant impairment. In this context, the Asset Management Company of the investment fund satisfied itself in line with numerous national guidelines and following discussions with the most important service providers (especially the Depositary, the portfolio management and the fund administration) that the measures taken and the business continuity plans put in place (including extensive hygiene measures on the premises, restrictions on business travel and events, precautions to ensure the reliable and smooth running of business processes in the event of a suspected case of coronavirus infection, expansion of the technical options for mobile working) will curb the currently foreseeable or ongoing operational risks and will ensure that the investment fund's activities will not be disrupted.

At the time of preparing this report, the Asset Management Company is of the opinion that there are no signs indicating any doubt on the ability of the respective investment fund to continue as a going concern, nor were there any liquidity problems for the investment fund.

Semiannual report

DWS Health Care Typ O

DWS HEALTH CARE TYP O

Performance of unit classes vs. benchmark (in EUR)

Unit class	ISIN	6 months
Class NC	DE0009769851	10.3%
Class FC	DE000DWS2ED9	10.7%
MSCI World Health Care TR Net		8.9%

"BVI method" performance, i.e., excluding the initial sales charge.
Past performance is no guide to future results.

As of: March 31, 2022

DWS HEALTH CARE TYP O

Overview of the unit classes

ISIN	NC	DE0009769851
	FC	DE000DWS2ED9
Security code (WKN)	NC	976985
	FC	DWS2ED
Fund currency		EUR
Unit class currency	NC	EUR
	FC	EUR
Date of inception and initial subscription	NC	November 10, 1997 (as of December 1, 2015, as NC unit class)
	FC	December 1, 2016
Initial sales charge	NC	None
	FC	None
Distribution policy	NC	Reinvestment
	FC	Reinvestment
All-in fee	NC	1.7% p.a.
	FC	0.85% p.a.
Minimum investment	NC	None
	FC	EUR 2,000,000
Initial issue price	NC	DEM 100
	FC	Net asset value per unit of the DWS Health Care Typ O NC unit class on the inception date of the FC unit class
Performance-based fee	NC	Yes
	FC	No

DWS Health Care Typ O

Statement of net assets as of March 31, 2022

	Amount in EUR	% of net assets
I. Assets		
1. Equities (sectors):		
Health Care	353 883 601.04	96.11
Total equities:	353 883 601.04	96.11
2. Investment fund units	0.12	0.00
3. Cash at bank	14 467 634.53	3.93
4. Other assets	359 757.70	0.10
II. Liabilities		
1. Other liabilities	-515 605.13	-0.14
III. Net assets	368 195 388.26	100.00

Negligible rounding errors may have arisen due to the rounding of calculated percentages.

DWS Health Care Typ O

Investment portfolio – March 31, 2022

Security name	Count/ currency (- / '000)	Quantity/ principal amount	Purchases/ additions in the reporting period	Sales/ disposals	Market price	Total market value in EUR	% of net assets
Securities traded on an exchange						353 883 601.04	96.11
Equities							
Bayer (DE000BAY0017)	Count	150 000			EUR 62.2700	9 340 500.00	2.54
Fresenius Medical Care (DE0005785802)	Count	150 000	150 000		EUR 60.6000	9 090 000.00	2.47
Grifols Cl.A (ES0171996087)	Count	150 000			EUR 16.3500	2 452 500.00	0.67
Koninklijke Philips (NL0000009538)	Count	460 000	90 000		EUR 28.1150	12 932 900.00	3.51
Merck (DE0006599005)	Count	71 500	7 000		EUR 192.9000	13 792 350.00	3.75
Sanofi (FR0000120578)	Count	55 000		35 000	EUR 93.4100	5 137 550.00	1.40
Sartorius Pref. (DE0007165631)	Count	16 500	16 500		EUR 406.6000	6 708 900.00	1.82
Siemens Healthineers (DE000SHL1006)	Count	115 000	115 000		EUR 55.9600	6 435 400.00	1.75
AstraZeneca (GB0009895292)	Count	117 000		23 000	GBP 102.2600	14 104 827.59	3.83
GlaxoSmithKline (GB0009252882)	Count	400 000			GBP 16.6300	7 842 027.70	2.13
Hoya (JP3837800006)	Count	35 400			JPY 14 030.0000	3 652 195.01	0.99
Surgical Science Sweden (SE0014428512)	Count	81 237	46 237		SEK 203.5000	1 600 330.05	0.43
Abbott Laboratories (US0028241000)	Count	130 000			USD 120.3800	14 060 557.05	3.82
Agilent Technologies (US00846U1016)	Count	72 000	55 000		USD 135.4600	8 762 911.05	2.38
Becton, Dickinson & Co. (US0758871091)	Count	71 250			USD 269.5900	17 258 119.95	4.69
Biogen (US09062X1037)	Count	15 000			USD 211.0300	2 844 070.08	0.77
Bio-Techne (US09073M1045)	Count	6 957	6 957		USD 442.3800	2 765 173.10	0.75
Bristol-Myers Squibb Co. (US1101221083)	Count	200 000		60 000	USD 73.7200	13 247 079.96	3.60
Centene (US15135B1017)	Count	180 000		45 700	USD 86.3600	13 966 576.82	3.79
Danaher Corp. (US2358511028)	Count	55 000	55 000		USD 297.3600	14 694 339.62	3.99
Eli Lilly and Company (US5324571083)	Count	55 000			USD 289.8900	14 325 202.16	3.89
Exact Sciences Corp. (US30063P1057)	Count	25 844	5 844		USD 71.3200	1 656 059.37	0.45
Guardant Health Cl.A (US40131M1099)	Count	27 035	19 335		USD 66.9900	1 627 200.94	0.44
HCA Healthcare (US40412C1018)	Count	25 000			USD 254.9600	5 726 864.33	1.56
Illumina (US4523271090)	Count	11 153	11 153		USD 352.0400	3 527 674.86	0.96
Intellia Therapeutics (US45826J1051)	Count	21 874	11 874		USD 72.1800	1 418 567.22	0.39
IQVIA Holdings (US46266C1053)	Count	70 000	70 000		USD 231.3200	14 548 427.67	3.95
Johnson & Johnson (US4781601046)	Count	123 000	18 000		USD 179.5900	19 846 873.32	5.39
Laboratory Corp. America Holdings (US50540R4092)	Count	32 000			USD 269.0000	7 734 052.11	2.10
Medtronic (IE00BTN1Y115)	Count	235 000			USD 111.5600	23 554 896.68	6.40
Merck & Co. (US58933Y1055)	Count	180 000		55 000	USD 82.4000	13 326 145.55	3.62
Organon & Co (US68622V1061)	Count	130 000			USD 35.8100	4 182 659.48	1.14
Pfizer (US7170811035)	Count	420 000	50 000		USD 52.4400	19 788 679.25	5.37
Steris (IE00BFY8C754)	Count	35 000	11 000		USD 245.8900	7 732 389.94	2.10
Teladoc Health (US87918A1051)	Count	50 500	36 200		USD 73.0700	3 315 395.33	0.90
UnitedHealth Group (US91324P1021)	Count	66 000		18 000	USD 520.8200	30 884 204.85	8.39
Investment fund units						0.12	0.00
In-group fund units (incl. units of funds issued by the asset management company)						0.12	0.00
DWS Deutsche GLS- Managed Dollar Fund Z (IE00BYQNZ507) (0.000%)	Count				USD 10 413.2222	0.12	0.00
Total securities portfolio						353 883 601.16	96.11
Cash and non-securitized money market instruments						14 467 634.53	3.93
Cash at bank						14 467 634.53	3.93
Demand deposits at Depository							
EUR deposits		EUR 165 625.31			% 100	165 625.31	0.05
Deposits in other EU/EEA currencies		EUR 77 064.80			% 100	77 064.80	0.02
Deposits in non-EU/EEA currencies							
Australian dollar	AUD	8 657.52			% 100	5 816.08	0.00
Brazilian real	BRL	25 840.96			% 100	4 866.47	0.00
Canadian dollar	CAD	66 268.14			% 100	47 536.42	0.01
Swiss franc	CHF	43 523.21			% 100	42 284.28	0.01
British pound	GBP	95 039.48			% 100	112 041.83	0.03
Hong Kong dollar	HKD	413 156.02			% 100	47 412.08	0.01
Japanese yen	JPY	9 355 062.00			% 100	68 792.28	0.02
Mexican peso	MXN	2 026.23			% 100	91.60	0.00
Turkish lira	TRY	727.19			% 100	44.61	0.00
U.S. dollar	USD	15 450 007.66			% 100	13 881 408.50	3.77
South African rand	ZAR	236 146.31			% 100	14 650.27	0.01

DWS Health Care Typ O

Security name	Count/ currency (- / '000)	Quantity/ principal amount	Purchases/ additions in the reporting period	Sales/ disposals	Market price	Total market value in EUR	% of net assets
Other assets						359 757.70	0.10
Dividends/Distributions receivable	EUR	352 106.39		%	100	352 106.39	0.10
Withholding tax claims	EUR	7 651.31		%	100	7 651.31	0.00
Other liabilities						-515 605.13	-0.14
Liabilities from cost items	EUR	-515 239.77		%	100	-515 239.77	-0.14
Additional other liabilities	EUR	-365.36		%	100	-365.36	0.00
Net assets						368 195 388.26	100.00

Net asset value per unit and number of units outstanding	Count/ currency	Net asset value per unit in the respective currency
Net asset value per unit		
Class NC	EUR	372.43
Class FC	EUR	388.50
Number of units outstanding		
Class NC	Count	987 844.131
Class FC	Count	741.000

Negligible rounding errors may have arisen due to the rounding of calculated percentages.

Exchange rates (indirect quotes)

As of March 31, 2022

Australian dollar	AUD	1.488550	= EUR	1
Brazilian real	BRL	5.310000	= EUR	1
Canadian dollar	CAD	1.394050	= EUR	1
Swiss franc	CHF	1.029300	= EUR	1
British pound	GBP	0.848250	= EUR	1
Hong Kong dollar	HKD	8.714150	= EUR	1
Japanese yen	JPY	135.990000	= EUR	1
Mexican peso	MXN	22.120050	= EUR	1
Swedish krona	SEK	10.330200	= EUR	1
Turkish lira	TRY	16.301850	= EUR	1
U.S. dollar	USD	1.113000	= EUR	1
South African rand	ZAR	16.118900	= EUR	1

Transactions completed during the reporting period that no longer appear in the investment portfolio

Purchases and sales of securities, investment fund units and promissory note loans (Schuldscheindarlehen); market classifications are as of the reporting date

Security name	Count/ currency (- / '000)	Purchases/ additions	Sales/ disposals
---------------	----------------------------------	-------------------------	---------------------

Securities traded on an exchange

Equities

Fresenius (DE0005785604)	Count	285 000
AbbVie (US00287Y1091)	Count	141 300
American Well Corp (US03044L1052)	Count	190 000
Amgen (US0311621009)	Count	45 000
AtriCure (US04963C2098)	Count	27 000
Cerner Corp. (US1567821046)	Count	54 000
McKesson Corp. (US58155Q1031)	Count	21 500
Oscar Health Cl.A (US6877931096)	Count	115 000
Silk Road Medical (US82710M1009)	Count	35 000

Securities loans (total transactions, at the value agreed at the closing of the loan contract)

No fixed maturity	EUR	3 541
-------------------	-----	-------

Security description: Grifols Cl.A (ES0171996087), Koninklijke Philips (NL0000009538)

DWS Health Care Typ O

Notes to the financial statements (in accordance with article 7, no. 9, KARBV (Accounting and Valuation Regulation issued under the KAGB))

Other disclosures

Net asset value per unit, Class NC:	EUR 372.43
Net asset value per unit, Class FC:	EUR 388.50

Number of units outstanding, Class NC:	987 844.131
Number of units outstanding, Class FC:	741.000

Disclosure regarding asset valuation procedures:

The Depositary shall determine the value with the participation of the asset management company. The Depositary generally bases its valuation on external sources.

If no trading prices are available, prices are determined with the aid of valuation models (derived market values) which are agreed between the Depositary and the asset management company and which are based as far as possible on market parameters. This procedure is subject to an ongoing monitoring process. The plausibility of price information from third parties is checked through other pricing sources, model calculations or other suitable procedure.

Investments reported in this report are not valued at derived market values.

For investment fund units, the management fee / all-in fee rates in effect as of the reporting date for the investment funds held in the securities portfolio are shown in parentheses in the investment portfolio. A plus sign means that a performance-based fee may also be charged. As the fund held units of other investment funds (target funds) in the reporting period, further costs, charges and fees may have been incurred at the level of these individual target funds.

DWS Health Care Typ O

Information pursuant to Regulation (EU) 2015/2365 on transparency of securities financing transactions (SFTs) and of reuse and amending Regulation (EU) No. 648/2012 –
Statement in accordance with Section A

	Securities lending	Repurchase agreements	Total return swaps
Stated in fund currency			
1. Assets used			
Absolute	-	-	-
In % of the fund's net assets	-	-	-
2. The 10 largest counterparties			
1. Name			
Gross volume of open transactions			
Country of registration			
2. Name			
Gross volume of open transactions			
Country of registration			
3. Name			
Gross volume of open transactions			
Country of registration			
4. Name			
Gross volume of open transactions			
Country of registration			
5. Name			
Gross volume of open transactions			
Country of registration			
6. Name			
Gross volume of open transactions			
Country of registration			
7. Name			
Gross volume of open transactions			
Country of registration			
8. Name			
Gross volume of open transactions			
Country of registration			

DWS Health Care Typ O

9. Name			
Gross volume of open transactions			
Country of registration			

10. Name			
Gross volume of open transactions			
Country of registration			

3. Type(s) of settlement and clearing			
(e.g., bilateral, tri-party, central counterparty)	-	-	-

4. Transactions classified by term to maturity (absolute amounts)			
Less than 1 day	-	-	-
1 day to 1 week	-	-	-
1 week to 1 month	-	-	-
1 to 3 months	-	-	-
3 months to 1 year	-	-	-
More than 1 year	-	-	-
No fixed maturity	-	-	-

5. Type(s) and quality/qualities of collateral received			
Type(s):			
Bank balances	-	-	-
Bonds	-	-	-
Equities	-	-	-
Other	-	-	-

Quality/Qualities:
Insofar as securities lending transactions, reverse repurchase agreements or transactions with OTC derivatives (except forward currency transactions) are concluded, collateral in one of the following forms is provided to the fund:
– Liquid assets such as cash, short-term bank deposits, money market instruments according to the definition in Directive 2007/16/EC of March 19, 2007, letters of credit and first-demand guarantees that are issued by top-rated credit institutions not affiliated with the counterparty, or bonds issued by an OECD member country or its local authorities or by supranational institutions and authorities at local, regional or international level, regardless of their term to maturity
– Units of a collective investment undertaking (hereinafter "UCI") investing in money market instruments that calculates a net asset value daily and has a rating of AAA or an equivalent rating
– Units of a UCITS that invests predominantly in the bonds and equities listed under the next two indents
– Bonds, regardless of their term to maturity, that have a minimum rating of low investment-grade
– Equities admitted to or traded in a regulated market in a member state of the European Union or on an exchange in an OECD member country, provided that these equities are included in a major index
The Management Company reserves the right to restrict the permissibility of the aforementioned collateral. Furthermore, the Management Company reserves the right to deviate from the aforementioned criteria in exceptional cases.
Additional information on collateral requirements can be found in the sales prospectus for the fund/sub-fund.

DWS Health Care Typ O

6. Currency/Currencies of collateral received			
Currency/Currencies:	-	-	-

7. Collateral classified by term to maturity (absolute amounts)			
Less than 1 day	-	-	-
1 day to 1 week	-	-	-
1 week to 1 month	-	-	-
1 to 3 months	-	-	-
3 months to 1 year	-	-	-
More than 1 year	-	-	-
No fixed maturity	-	-	-

8. Income and cost portions (before income adjustment)*			
Income portion of the fund			
Absolute	333.01	-	-
In % of gross income	67.00	-	-
Cost portion of the fund	-	-	-

Income portion of the Management Company			
Absolute	-	-	-
In % of gross income	-	-	-
Cost portion of the Management Company	-	-	-

Income portion of third parties			
Absolute	-	-	-
In % of gross income	-	-	-
Cost portion of third parties	-	-	-

9. Income for the fund from reinvestment of cash collateral, based on all SFTs and total return swaps	
Absolute	-

10. Lent securities in % of all lendable assets of the fund	
Total	-
Share	-

11. The 10 largest issuers, based on all SFTs and total return swaps			
1. Name			
Volume of collateral received (absolute)			
2. Name			
Volume of collateral received (absolute)			

DWS Health Care Typ O

3. Name			
Volume of collateral received (absolute)			
4. Name			
Volume of collateral received (absolute)			
5. Name			
Volume of collateral received (absolute)			
6. Name			
Volume of collateral received (absolute)			
7. Name			
Volume of collateral received (absolute)			
8. Name			
Volume of collateral received (absolute)			
9. Name			
Volume of collateral received (absolute)			
10. Name			
Volume of collateral received (absolute)			

12. Reinvested collateral in % of collateral received, based on all SFTs and total return swaps

Share		-
--------------	--	---

13. Custody type of provided collateral from SFTs and total return swaps
(In % of all provided collateral from SFTs and total return swaps)

Segregated cash/custody accounts	-	-
Pooled cash/custody accounts	-	-
Other cash/custody accounts	-	-
Recipient determines custody type	-	-

DWS Health Care Typ O

14. Depositories/Account holders of received collateral from SFTs and total return swaps

Total number of depositaries/
account holders

-	-	-
---	---	---

1. Name

Amount held in custody
(absolute)

* Any deviations compared to the corresponding information in the detailed statement of income and expenses are based on effects due to income adjustment.

Asset Management Company

DWS Investment GmbH
60612 Frankfurt/Main, Germany
Own funds on
December 31, 2021: EUR 115.0 million
Subscribed and paid-in capital
on December 31, 2021: EUR 451.9 million

Supervisory Board

Dr. Asoka Wöhrmann
Chairman
DWS Management GmbH
(personally liable partner of
DWS Group GmbH & Co. KGaA),
Frankfurt/Main

Christof von Dryander
Vice-Chairman
Cleary Gottlieb Steen & Hamilton LLP,
Frankfurt/Main

Hans-Theo Franken
Deutsche Vermögensberatung AG,
Frankfurt/Main

Dr. Alexander Ilgen
Deutsche Bank AG,
Frankfurt/Main

Britta Lehfeldt (until October 31, 2021)
Deutsche Bank AG,
Frankfurt/Main

Dr. Stefan Marcinowski
Ludwigshafen

Prof. Christian Strenger
The Germany Funds,
New York

Elisabeth Weisenhorn
(since February 10, 2022)
Portikus Investment GmbH,
Frankfurt/Main

Gerhard Wiesheu
Partner of Bankhaus
B. Metzler seel. Sohn & Co. KGaA,
Frankfurt/Main

Susanne Zeidler
Frankfurt/Main

Management

Manfred Bauer
Speaker of the Management

Member of the Management of
DWS Management GmbH
(personally liable partner of
DWS Group GmbH & Co. KGaA),
Frankfurt/Main
Member of the Management of
DWS Beteiligungs GmbH,
Frankfurt/Main
Member of the Supervisory Board of
DWS Investment S.A.,
Luxembourg

Dirk Görgen

Member of the Management of
DWS Management GmbH
(personally liable partner of
DWS Group GmbH & Co. KGaA),
Frankfurt/Main
Member of the Management of
DWS Beteiligungs GmbH,
Frankfurt/Main

Stefan Kreuzkamp

Member of the Management of
DWS Management GmbH
(personally liable partner of
DWS Group GmbH & Co. KGaA),
Frankfurt/Main

Member of the Management of
DWS Beteiligungs GmbH,
Frankfurt/Main

Member of the Supervisory Board of
DWS Investment S.A.,
Luxembourg

Dr. Matthias Liermann

Member of the Management of
DWS International GmbH,
Frankfurt/Main

Member of the Management of
DWS Beteiligungs GmbH,
Frankfurt/Main

Member of the Supervisory Board of
DWS Investment S.A.,
Luxembourg

Member of the Supervisory Board of
Deutsche Treuinvest Stiftung,
Frankfurt/Main

Petra Pflaum

Member of the Management of
DWS Beteiligungs GmbH,
Frankfurt/Main

Depository

State Street Bank International GmbH
Briener Straße 59
80333 München, Germany
Own funds on December 31, 2020:
EUR 2,302.0 million
(as defined in article 72 of Regulation (EU)
No. 575/2013 (CRR))
Subscribed and paid-in capital on
December 31, 2020: EUR 109.4 million

**Shareholder of
DWS Investment GmbH**

DWS Beteiligungs GmbH,
Frankfurt/Main



DWS Investment GmbH
60612 Frankfurt/Main, Germany
Tel.: +49 (0) 69-910-12371
Fax: +49 (0) 69-910-19090
www.dws.com